Recombinant Human LCN1, N-His

Description of Recombinant Human LCN1, N-His

Introduction

Recombinant Human LCN1, N-His is a protein that has been genetically engineered for use in various scientific and medical applications. This protein is a variant of the human Lipocalin-1 (LCN1) protein, which is involved in various physiological processes such as inflammation, immune response, and lipid metabolism. The addition of a Histidine (His) tag to the N-terminus of the protein allows for easier purification and detection. In this article, we will discuss the structure, activity, and potential applications of Recombinant Human LCN1, N-His as a drug target.

Structure of Recombinant Human LCN1, N-His

Recombinant Human LCN1, N-His is a 19 kDa protein composed of 180 amino acids. It is a member of the Lipocalin family, which are small, secreted proteins that bind and transport hydrophobic molecules. The protein contains a characteristic beta-barrel structure, with eight beta-strands forming a cup-like shape. The N-His tag is located at the N-terminus of the protein and consists of six Histidine residues, which allows for easy purification using metal affinity chromatography.

Activity of this protein

The primary function of Recombinant Human LCN1, N-His is to bind and transport hydrophobic molecules, such as lipids and steroids. This activity is essential for lipid metabolism and immune response. Additionally, the protein has been shown to have anti-inflammatory properties by inhibiting the activity of certain enzymes involved in the inflammatory response. The N-His tag does not affect the activity of the protein and is solely used for purification and detection purposes.

Role as a Drug Target

Recombinant Human LCN1, N-His has been identified as a potential drug target for various diseases and conditions. Its involvement in lipid metabolism makes it a potential target for metabolic disorders such as obesity and dyslipidemia. The anti-inflammatory properties of the protein also make it a promising target for inflammatory diseases such as rheumatoid arthritis and asthma.

Targeting Recombinant Human LCN1, N-His in Obesity

Obesity is a growing health concern worldwide, and current treatments often have limited efficacy and significant side effects. Recombinant Human LCN1, N-His has been shown to regulate lipid metabolism by binding and transporting lipids. This activity can potentially be targeted to regulate lipid levels in obese individuals and aid in weight loss. Furthermore, the anti-inflammatory properties of the protein can help reduce inflammation associated with obesity.

Targeting Recombinant Human LCN1, N-His in Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis and asthma, are characterized by chronic inflammation. Recombinant Human LCN1, N-His has been shown to inhibit the activity of enzymes involved in the inflammatory response, making it a potential target for these diseases. By targeting this protein, it may be possible to reduce inflammation and alleviate symptoms in patients with these conditions.

Conclusion

In summary, Recombinant Human LCN1, N-His is a genetically engineered protein with a unique structure and activity. Its ability to bind and transport hydrophobic molecules, as well as its anti-inflammatory properties, make it a promising drug target for various diseases and conditions. Further research and development of this protein may lead to new and effective treatments for obesity, inflammatory diseases, and other related conditions.